Compare Cytokinetics Inc (CYTK) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Endeavour Silver Corp — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Endeavour Silver Corp trades at $8.78 (market cap $2.54B). The key difference: Cytokinetics Inc is far larger — about 3.4× Endeavour Silver Corp's market cap, and Endeavour Silver Corp is more actively traded (7,077,330 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Endeavour Silver Corp for 25 Days on average.
| CYTK | EXK | |
|---|---|---|
Market Cap | $8.62B | $2.54B |
Volume | 2,594,626 | 7,077,330 |
Sector | Health | Basic Materials |
52-Week High | $87.26 | $14.12 |
52-Week Low | $54.76 | $7.07 |
Typical Hold Time | 19 Days | 25 Days |
Enterprise Value | $8.72B | $2.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Endeavour Silver (EXK) trades at $8.32, down 4.04% today, amid a bearish technical signal. The company reported mixed Q2 2026 earnings, matching estimates with $0.15 EPS, but showed strong revenue growth and improved profitability in 2026. Recent news highlights operational progress at Terronera and Kolpa mines, though temporary disruptions occurred. Analyst consensus remains strongly bullish with a $10.50 price target.
Outlook is cautiously optimistic driven by production growth and favorable metal prices, but risks include operational disruptions and high valuation multiples. The stock offers potential upside from current levels if execution continues, but volatility from commodity prices and mine-specific issues persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
